Pfizer and Astellas gain positive trial results for prostate cancer treatment

Pfizer and Astellas have announced results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Enzalutamide had significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use. The results, which are for the drug in combination with androgen deprivation therapy, show a

Continue Reading